ICON PLC ICLR

Industrials SIC 8731 - Services-Commercial Physical & Biological Research NAICS Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS2.90

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $8.25B$8.19B$8.05B$7.74B$5.48B$2.80B$2.81B$2.60B$1.76B$1.67B
Cost of revenue —$5.85B$5.72B$5.53B$3.97B$1.98B$1.97B$1.82B$1.03B$961.3M
Gross profit —$2.34B$2.33B$2.21B$1.51B$817.4M$831.7M$777.6M$731.1M$705.2M
SG&A $780.1M$728.3M$768.6M$778.8M$585.3M$342.4M$332.7M$325.8M$323.7M$325.7M
Total operating expenses $7.81B$7.16B$7.15B$6.95B$5.10B$2.41B$2.37B$2.22B$1.42B$1.35B
Operating income $442.8M$1.03B$904.7M$795.2M$378.5M$391.5M$433.4M$373.4M$338.3M$311.7M
Interest expense $197.5M$237.2M$336.7M$229.7M$182.4M$13.0M$13.3M———
Pre-tax income $252.5M$803.8M$573.0M$567.9M$196.7M$381.2M$427.0M$364.6M$328.1M$300.2M
Income tax $23.1M$64.6M$18.4M$59.4M$41.3M$47.9M$51.1M$42.0M$46.6M$38.0M
Net income $229.3M$739.1M$554.2M$505.3M$153.2M$332.3M$374.0M$322.7M$281.5M$262.2M
EPS, basic 2.928.966.756.202.286.206.855.965.204.75
EPS, diluted 2.908.906.706.132.256.156.795.895.134.65
Shares, diluted (wtd. avg.) 79.0M83.0M82.7M82.5M68.1M53.3M54.3M54.8M54.8M56.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $647.3M$538.8M$378.1M$288.8M$752.2M$840.3M$520.3M$395.9M$282.9M$192.5M
Short-term investments $0$0$2.0M$1.7M$1.7M$1.7M$49.6M$59.9M$77.6M$68.0M
Receivables $1.47B$1.39B$1.76B$1.73B$1.34B$715.3M$527.7M$414.8M$379.5M$416.2M
Inventory ————$5.8M$4.8M$3.2M$2.3M$2.2M$2.4M
Total current assets $3.50B$3.28B$3.29B$3.23B$2.94B$2.10B$1.62B$1.33B$1.10B$958.0M
Property, plant and equipment $395.7M$382.9M$361.2M$350.3M$336.4M$174.3M$165.1M$158.7M$163.1M$149.0M
Goodwill $8.73B$9.05B$9.02B$8.97B$9.04B$936.3M$883.2M$756.3M$769.1M$616.1M
Other intangibles $3.25B$3.56B$3.86B$4.28B$4.71B$66.5M$67.9M$54.1M$71.6M$56.6M
Total assets $16.27B$16.63B$16.86B$17.19B$17.39B$3.44B$2.91B$2.35B$2.15B$1.83B
Accounts payable $192.1M$173.0M$131.6M$81.2M$90.8M$51.1M$24.1M$13.3M$18.6M$8.7M
Total current liabilities $3.20B$2.64B$2.73B$2.69B$2.48B$1.12B$1.13B$610.6M$566.1M$494.4M
Long-term debt $2.87B$3.40B$3.67B$4.60B$5.38B$348.5M————
Total liabilities $7.08B$7.19B$7.65B$8.69B$9.32B$1.59B$1.25B$1,000.0M$955.6M$880.7M
Retained earnings $2.12B$2.64B$2.40B$1.82B$1.42B$1.26B$1.11B$888.3M$742.8M$587.8M
Total equity $9.19B$9.44B$9.21B$8.53B$8.07B$1.85B$1.62B$1.35B$1.19B$945.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.04B$1.29B$1.16B$563.3M$829.1M$568.0M$412.5M$268.6M$383.1M$259.2M
Depreciation and amortisation $383.0M$488.5M$586.0M$569.5M$315.0M$66.1M$61.5M$50.6M$43.4M$42.1M
Stock-based compensation $102.0M$45.9M$55.7M$70.5M$133.8M$26.3M$26.8M$31.6M$30.6M$40.3M
Capital expenditure $174.2M$168.1M$140.7M$142.2M$93.8M$40.9M$38.9M$48.4M$44.7M$42.6M
Investing cash flow -$187.5M-$266.8M-$226.7M-$145.9M-$6.02B-$46.6M-$162.0M-$37.3M-$177.8M-$74.8M
Financing cash flow -$771.3M-$837.2M-$844.0M-$864.2M$5.11B-$208.3M-$125.4M-$113.0M-$119.3M-$93.7M
Buybacks $750.0M$500.0M$0$100.0M$0$175.0M$146.9M$129.0M$133.1M$110.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-038487.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 2.5B 5B 7.5B 10B Revenue, FY2016: 1.7B Gross profit, FY2016: 705.2M Net income, FY2016: 262.2M Revenue, FY2017: 1.8B Gross profit, FY2017: 731.1M Net income, FY2017: 281.5M Revenue, FY2018: 2.6B Gross profit, FY2018: 777.6M Net income, FY2018: 322.7M Revenue, FY2019: 2.8B Gross profit, FY2019: 831.7M Net income, FY2019: 374M Revenue, FY2020: 2.8B Gross profit, FY2020: 817.4M Net income, FY2020: 332.3M Revenue, FY2021: 5.5B Gross profit, FY2021: 1.5B Net income, FY2021: 153.2M Revenue, FY2022: 7.7B Gross profit, FY2022: 2.2B Net income, FY2022: 505.3M Revenue, FY2023: 8.1B Gross profit, FY2023: 2.3B Net income, FY2023: 554.2M Revenue, FY2024: 8.2B Gross profit, FY2024: 2.3B Net income, FY2024: 739.1M Revenue, FY2025: 8.3B Net income, FY2025: 229.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.67B $1.76B $2.60B $2.81B $2.80B $5.48B $7.74B $8.05B $8.19B $8.25B
Gross profit $705.2M $731.1M $777.6M $831.7M $817.4M $1.51B $2.21B $2.33B $2.34B —
Net income $262.2M $281.5M $322.7M $374.0M $332.3M $153.2M $505.3M $554.2M $739.1M $229.3M

Others in SIC 8731

TickerCompanyMarket capP/ERevenue growth
IQV IQVIA HOLDINGS INC. $46.63B 35.6x 5.9%
INCY INCYTE CORP $23.12B 18.1x 21.2%
MEDP Medpace Holdings, Inc. $18.68B 43.8x 20.0%
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $16.49B — -0.9%
ABSI Absci Corp $1.58B — -38.2%
OABI OmniAb, Inc. $677.5M — -29.3%
NRC NRC HEALTH $485.1M 0.4x -4.0%
ONMD OneMedNet Corp $279.2M — 111.4%